Filtered By:
Source: The American Journal of Cardiology
Condition: Heart Failure
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 105 results found since Jan 2013.
Effect of Gender on Patients with ST-elevation and Non-ST-elevation Myocardial Infarction without Obstructive Coronary Artery Disease
We compared the prognosis of patients with ST-elevation MI (STEMI) with non-ST-elevation MI (NSTEMI) without obstructive coronary artery disease (CAD) and the risk associated with gender for future cardiovascular (CV) events. The study population was selected from 95,849 patients undergoing coronary angiography for MI during the period 2005-2010 and registered in the Swedish Coronary Angiography and Angioplasty Registry. Outcome analyses, including all-cause death, MI, congestive heart failure (CHF), stroke and revascularization, were performed on 2268 STEMI patients and 10,904 NSTEMI patients without obstructive CAD (
Source: The American Journal of Cardiology - March 24, 2015 Category: Cardiology Authors: Nina Johnston, Birgitta Jönelid, Christina Christersson, Tanja Kero, Henrik Renlund, Karin Schenck-Gustafsson, Bo Lagerqvist Source Type: research
Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women
In this study, we sought to identify the risk and risk factors for adverse maternal and fetal events in pregnant women with underlying heart disease. Pregnant women referred for echocardiogram with known or suspected heart disease were categorized into those with: (1) cardiomyopathy, (2) other heart disease (HD; congenital, coronary, arrhythmia, or valvular), and (3) no HD. Primary outcome was major adverse cardiovascular events (MACE), defined as a composite of death, sustained arrhythmia, myocardial infarction, heart failure, and transient ischemic attack/stroke.
Source: The American Journal of Cardiology - May 8, 2015 Category: Cardiology Authors: Paraskevi Koutrolou-Sotiropoulou, Puja B. Parikh, Charles Miller, Fabio Vasconcelos Lima, Javed Butler, Kathleen Stergiopoulos Source Type: research
Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin
We sought to assess the performance of existing bleeding risk scores, such as the Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly (HAS-BLED) score or the Outpatient Bleeding Risk Index (OBRI), in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Source: The American Journal of Cardiology - June 24, 2015 Category: Cardiology Authors: Siqin Ye, Bin Cheng, Gregory Y.H. Lip, Richard Buchsbaum, Ralph L. Sacco, Bruce Levin, Marco R. Di Tullio, Min Qian, Douglas L. Mann, Patrick M. Pullicino, Ronald S. Freudenberger, John R. Teerlink, J.P. Mohr, Susan Graham, Arthur J. Labovitz, Conrado J. Tags: Heart Failure Source Type: research
Influence of Cardiovascular and Non-Cardiovascular Comorbidities on Outcomes and Treatment Effect of Heart Rate Reduction with Ivabradine in Stable Heart Failure – (from the SHIFT trial)
Incidence of chronic heart failure (HF) increases with age and cardiovascular morbidity. Comorbidities increase hospitalization and mortality in HF, and non-cardiovascular comorbidities may lead to preventable hospitalizations. We studied the impact of comorbidities on mortality and morbidity in SHIFT, and investigated whether the impact of ivabradine was affected by comorbidities. We analyzed the SHIFT population, with moderate to severe HF and left ventricular dysfunction (in sinus rhythm with resting heart rate ≥70 bpm), according to comorbidity: chronic obstructive pulmonary disease, diabetes mellitus, anemia, stroke...
Source: The American Journal of Cardiology - October 5, 2015 Category: Cardiology Authors: Michael Böhm, Michele Robertson, Ian Ford, Jeffrey S. Borer, Michel Komajda, Ingrid Kindermann, Christoph Maack, Mitja Lainscak, Karl Swedberg, Luigi Tavazzi Source Type: research
Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With in Stable Heart Failure (from the SHIFT Trial)
Incidence of chronic heart failure (HF) increases with age and cardiovascular (CV) morbidity. Co-morbidities increase hospitalization and mortality in HF, and non-CV co-morbidities may lead to preventable hospitalizations. We studied the impact of co-morbidities on mortality and morbidity in Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial, and investigated whether the impact of ivabradine was affected by co-morbidities. We analyzed the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trialpopulation, with moderate-to-severe HF and left ventricular dysfunction (in sinus rhythm with h...
Source: The American Journal of Cardiology - October 5, 2015 Category: Cardiology Authors: Michael Böhm, Michele Robertson, Ian Ford, Jeffrey S. Borer, Michel Komajda, Ingrid Kindermann, Christoph Maack, Mitja Lainscak, Karl Swedberg, Luigi Tavazzi Tags: Heart Failure Source Type: research
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-Term Risk of Cardiac Death in Patients wtih Hypertrophic Cardiomyopathy
The Objective of this study is to investigate the prognostic significance of 12-lead electrocardiogram (ECG) patterns in a large multicenter cohort of patients with hypertrophic cardiomyopathy (HC). 1004 consecutive patients with HC and a recorded standard ECG (64% men, mean age 50±16 years) were evaluated at 4 Italian centres. The study end-points were sudden cardiac death (SCD) or surrogates, including appropriate implanted cardiac defibrillator discharge and resuscitated cardiac arrest) and major cardiovascular events (including SCD or surrogates and death due to heart failure, cardioembolic stroke or heart transplantation).
Source: The American Journal of Cardiology - May 14, 2016 Category: Cardiology Authors: Elena Biagini, Chiara Pazzi, Iacopo Olivotto, Beatrice Musumeci, Giuseppe Limongelli, Giuseppe Boriani, Giuseppe Pacileo, Vittoria Mastromarino, Maria Letizia Bacchi Reggiani, Massimiliano Lorenzini, Francesco Lai, Alessandra Berardini, Francesca Mingardi Source Type: research
Usefulness of Left Ventricular Mass and Geometry for Determining 10-Year Prediction of Cardiovascular Disease in Adults > 65 Years of Age (From the Cardiovascular Health Study)
Left ventricular (LV) mass and geometry are associated with risk of cardiovascular disease (CVD). We sought to determine whether LV mass and geometry contribute to risk prediction for CVD in adults ≥ 65 years of the Cardiovascular Health Study. We indexed LV mass to body size (echo-LVMI) and we defined LV geometry as normal, concentric remodeling, and eccentric or concentric LV hypertrophy. We added echo-LVMI and LV geometry to separate 10-year risk prediction models containing traditional risk factors and determined the net reclassification improvement (NRI) for incident CHD, CVD (CHD, heart failure [HF], stroke), and HF alone.
Source: The American Journal of Cardiology - June 12, 2016 Category: Cardiology Authors: Chintan S. Desai, Traci M. Bartz, John S. Gottdiener, Donald M. Lloyd-Jones, Julius M. Gardin Source Type: research
Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices
Within the last decade, advancements in left ventricular assist device (LVAD) therapy have allowed end-stage heart failure patients to live longer and with better quality of life. Like other life-saving interventions, however, there remains the risk of complications including infections, bleeding episodes, and stroke. The candidate for LVAD therapy faces complex challenges going forward, both physical and psychological, many of which may benefit from the application of palliative care principles by trained specialists.
Source: The American Journal of Cardiology - June 20, 2016 Category: Cardiology Authors: Nancy Luo, Joseph G. Rogers, Gwen C. Dodson, Chetan B. Patel, Anthony N. Galanos, Carmelo A. Milano, Christopher M. O’Connor, Robert J. Mentz Source Type: research
Usefulness of Left Ventricular Mass and Geometry for Determining 10-Year Prediction of Cardiovascular Disease in Adults Aged > 65 Years (from the Cardiovascular Health Study)
Left ventricular (LV) mass and geometry are associated with risk of cardiovascular disease (CVD). We sought to determine whether LV mass and geometry contribute to risk prediction for CVD in adults aged ≥65 years of the Cardiovascular Health Study. We indexed LV mass to body size, denoted as LV mass index (echo-LVMI), and we defined LV geometry as normal, concentric remodeling, and eccentric or concentric LV hypertrophy. We added echo-LVMI and LV geometry to separate 10-year risk prediction mode ls containing traditional risk factors and determined the net reclassification improvement (NRI) for incident coronary heart d...
Source: The American Journal of Cardiology - June 12, 2016 Category: Cardiology Authors: Chintan S. Desai, Traci M. Bartz, John S. Gottdiener, Donald M. Lloyd-Jones, Julius M. Gardin Tags: Preventive Cardiology Source Type: research
Usefulness of Atrial Fibrillation as a Marker for Adverse Cardiovascular Outcomes in Both Primary and Secondary Prevention in Patients with Implantable Cardioverter-Defibrillators
Whether the risk factors for cardiovascular (CV) outcomes are different in primary vs. secondary prevention implantable cardioverter-defibrillator (ICD) patients is unclear. We sought to identify predictors of CV outcomes in ICD recipients for primary (G1) vs. secondary prevention (G2). Consecutive patients who had ICD implanted during August 2005 –December 2009 were included. The primary outcome was a composite of appropriate shock, acute coronary syndrome, ischemic stroke, coronary revascularization, heart failure exacerbation, CV hospitalization, or all-cause death.
Source: The American Journal of Cardiology - August 22, 2016 Category: Cardiology Authors: Ian CY. Chang, Yusuf Agawami, Erin Austin, Wayne O. Adkisson, Henri Roukoz, Lisa N. von Wald, Scott Sakaguchi, David G. Benditt, Lin Y. Chen Source Type: research
Relation of the Myocardial Contraction Fraction, as Calculated from M-Mode Echocardiography, with Incident Heart Failure, Atherosclerotic Cardiovascular Disease and Mortality (Results from the Cardiovascular Health Study)
We evaluated the association between two-dimensional (2D) echocardiography (echo) determined myocardial contraction fraction (MCF) and adverse cardiovascular outcomes including incident heart failure (HF), atherosclerotic cardiovascular disease (ASCVD) and mortality. The MCF, the ratio of left ventricular (LV) stroke volume (SV) to myocardial volume (MV), is a volumetric measure of myocardial shortening that can distinguish pathologic from physiologic hypertrophy. Using 2D-echo-guided M-mode data from the Cardiovascular Health Study, we calculated MCF among individuals with LV ejection fraction (EF) ≥55%, and used Cox mo...
Source: The American Journal of Cardiology - December 16, 2016 Category: Cardiology Authors: Mathew S. Maurer, William Jen Hoe Koh, Traci M. Bartz, Sirish Vullaganti, Eddy Barasch, Julius M. Gardin, John S. Gottdiener, Bruce M. Psaty, Jorge R. Kizer Source Type: research
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD) - namely myocardial infarction, heart failure and stroke. Despite clear advances in the prevention and treatment of CVD, the impact of T2DM on CVD outcome remains high, and continues to escalate. Available evidence indicates that the risk of macrovascular complications increases with the severity of hyperglycemia, thus suggesting that the relation between metabolic disturbances and vascular damage is approximately linear.
Source: The American Journal of Cardiology - May 29, 2017 Category: Cardiology Authors: Francesco Paneni, Thomas F. L üscher Source Type: research
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Patients with type 2 diabetes (T2DM) have a significantly higher risk of developing cardiovascular disease (CVD) —namely myocardial infarction, heart failure, and stroke. Despite clear advances in the prevention and treatment of CVD, the impact of T2DM on CVD outcome remains high and continues to escalate. Available evidence indicates that the risk of macrovascular complications increases with the severity o f hyperglycemia, thus suggesting that the relation between metabolic disturbances and vascular damage is approximately linear.
Source: The American Journal of Cardiology - May 29, 2017 Category: Cardiology Authors: Francesco Paneni, Thomas F. L üscher Source Type: research
Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients with Atrial Fibrillation.
We investigated the incidence of non-embolic adverse events in 2 cohorts of AF patients and validated the 2MACE score [(metabolic syndrome, age ≥75) [doubled]; (myocardial infarction (MI)/revascularization, congestive heart failure (HF) and stroke/TIA/thromboembolism)] as predictor of major adverse cardiovascular events (MACEs). We recruited 2630 AF patients from two different cohorts (Murcia AF and FANTASIIA). The 2MACE score was calcula ted and during a median of 7.2 years (Murcia AF cohort) and 1.01 years (FANTASIIA) of follow-up we recorded all non-embolic adverse events and MACEs (composite of non-fatal MI/revascula...
Source: The American Journal of Cardiology - September 18, 2017 Category: Cardiology Authors: Jos é Miguel Rivera-Caravaca, Francisco Marín, María Asunción Esteve-Pastor, Paula Raña-Míguez, Manuel Anguita, Javier Muñiz, Ángel Cequier, Vicente Bertomeu-Martínez, Mariano Valdés, Vicente Vicente, Gregory Yoke Hong Lip, Vanessa Roldán Source Type: research
